Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:fatty acid 22:6
go back to main search page
Accession:CHEBI:132544 term browser browse the term
Definition:Any polyunsaturated fatty acid containing 22 carbons and 6 double bonds.
Synonyms:related_synonym: FA 22:6;   Formula=C22H32O2;   SMILES=C(=O)(O)*;   free fatty acid 22:6



show annotations for term's descendants           Sort by:
(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alox15 arachidonate 15-lipoxygenase multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in decreased expression of ALOX15 mRNA]] CTD PMID:34601004 NCBI chr10:55,559,060...55,567,535 JBrowse link
G Alox5 arachidonate 5-lipoxygenase decreases expression
multiple interactions
ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased expression of ALOX5 protein
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[[Dietary Fats co-treated with Cholesterol, Dietary] results in increased susceptibility to Silver Compounds] which results in decreased expression of ALOX5 mRNA]
CTD PMID:17056761 PMID:34601004 NCBI chr 4:151,203,948...151,251,126 JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 protein] CTD PMID:21724996 PMID:34601004 NCBI chr10:67,503,077...67,504,875 JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 protein]; [Silver Compounds results in increased susceptibility to 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid] which results in increased expression of CXCL2 mRNA CTD PMID:21724996 PMID:34601004 NCBI chr14:17,465,210...17,467,255 JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein] CTD PMID:21724996 NCBI chr14:17,571,900...17,573,624 JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA] CTD PMID:21724996 NCBI chr 8:27,829,688...27,841,618 JBrowse link
G Ifng interferon gamma multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein] CTD PMID:21724996 NCBI chr 7:55,789,180...55,793,216 JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein] CTD PMID:21724996 NCBI chr 3:137,030,200...137,036,581 JBrowse link
G Il6 interleukin 6 multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 protein] CTD PMID:21724996 PMID:34601004 NCBI chr 4:5,889,999...5,894,575 JBrowse link
G Itgal integrin subunit alpha L multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA] CTD PMID:21724996 NCBI chr 1:191,348,424...191,386,228 JBrowse link
G Mpo myeloperoxidase multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] CTD PMID:21724996 NCBI chr10:73,092,124...73,102,057 JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA] CTD PMID:21724996 NCBI chr 6:78,593,844...78,597,307 JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid binds to and affects the activity of PPARG protein CTD PMID:17056761 NCBI chr 4:150,095,743...150,221,104 JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] CTD PMID:21724996 NCBI chr13:64,714,063...64,722,320 JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein] CTD PMID:21724996 NCBI chr 1:212,354,336...212,364,815 JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases secretion
ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased secretion of TNF protein
CTD PMID:17056761 PMID:21724996 NCBI chr20:3,626,685...3,629,303 JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA] CTD PMID:21724996 NCBI chr 2:206,723,050...206,742,783 JBrowse link
1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Fech ferrochelatase affects abundance ISO FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine CTD PMID:29906468 NCBI chr18:57,945,123...57,978,327 JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19898
    chemical entity 19896
      atom 19896
        nonmetal atom 19818
          carbon atom 19770
            organic molecular entity 19770
              lipid 18003
                fatty acid 16855
                  fatty acid 22:6 18
                    docosahexaenoic acid + 18
Path 2
Term Annotations click to browse term
  CHEBI ontology 19898
    subatomic particle 19896
      composite particle 19896
        hadron 19896
          baryon 19896
            nucleon 19896
              atomic nucleus 19896
                atom 19896
                  main group element atom 19835
                    p-block element atom 19835
                      carbon group element atom 19774
                        carbon atom 19770
                          organic molecular entity 19770
                            heteroorganic entity 19535
                              organochalcogen compound 19296
                                organooxygen compound 19213
                                  carbon oxoacid 18682
                                    carboxylic acid 18679
                                      monocarboxylic acid 18028
                                        fatty acid 16855
                                          unsaturated fatty acid 1686
                                            polyunsaturated fatty acid 847
                                              fatty acid 22:6 18
                                                docosahexaenoic acid + 18
paths to the root